Novyra Pharmachem Other Announcement
Novyra Pharmachem intimated BSE of a change in its official email ID under Reg 30. The update is purely administrative with no business or financial impact.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
18 announcements with these filters
Novyra Pharmachem intimated BSE of a change in its official email ID under Reg 30. The update is purely administrative with no business or financial impact.
The company has officially changed its name from Bansisons Tea Industries Limited to Novyra Pharmachem Limited. This change reflects the company's expansion into the pharmaceutical sector.
Bansisons Tea Industries Ltd reported revenue from operations of ₹1.7 Cr and net profit of ₹0 Cr for Q1 FY27.
Novyra Pharmachem Limited has scheduled a board meeting for August 14, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026.
Novyra Pharmachem Limited has updated its official website address. The change is being intimated to the exchange for record-keeping purposes.
Bansisons Tea Industries Ltd has submitted its quarterly shareholding pattern for the period ended June 30, 2026, in compliance with SEBI Regulation 31(1)(b).
Novyra Pharmachem Limited held its 39th AGM on June 25, 2026 via video conference. The meeting adopted audited accounts, re-appointed a director and approved a capital reduction scheme.
Novyra Pharmachem Limited released its 39th Annual Report for FY2025-26. The report includes notice for the AGM and a proposed scheme for capital reduction.
Novyra Pharmachem Limited reported zero deviation in the utilization of ₹0.13 Crore raised via preferential issue. Funds were fully utilized for working capital requirements as intended.
Novyra Pharmachem Limited scheduled its 39th AGM for June 25, 2026, via VC/OAVM. Revised e-voting and book closure dates are also confirmed for shareholders.
Novyra Pharmachem approved a capital reduction proposal and scheduled its 39th AGM for June 19, 2026. These administrative steps align corporate structure with long-term strategy.
Novyra Pharmachem Limited (formerly Bansisons Tea Industries) has scheduled a Board meeting for May 16, 2026. The meeting will primarily consider a proposal for capital reduction under Section 66 of the Companies Act, 2013, alongside fixing dates for the Annual General Meeting and book closure.
Bansisons Tea Industries Ltd reported revenue from operations of ₹0.1 Cr and a net loss of ₹5.3 Cr for Q4 FY26.
Novyra Pharmachem Limited reported audited financial results for FY2026 with a total revenue of ₹0.17 Crore. The company recorded a net loss of ₹5.37 Crore for the year. The Board of Directors reviewed and approved these results at their meeting held on May 02, 2026.
Novyra Pharmachem Limited (formerly Bansisons Tea Industries Ltd) has postponed its board meeting from April 29, 2026, to May 2, 2026. The meeting was scheduled to approve audited financial results for the year ended March 31, 2026.
Novyra Pharmachem Limited confirmed it does not meet the SEBI criteria to be classified as a 'Large Corporate' for FY 2026. The company reported outstanding borrowings of ₹0.82 Crore as of March 31, 2026. This disclosure is a routine regulatory requirement regarding debt-raising frameworks.
Novyra Pharmachem Limited (formerly Bansisons Tea Industries Ltd) has postponed its Board Meeting originally scheduled for April 18, 2026. The meeting, intended to approve audited financial results for the year ended March 31, 2026, is now rescheduled to Saturday, April 25, 2026.
Bansisons Tea Industries Ltd reported net profit of ₹0 Cr for Q3 FY26.